Tue, May 13, 8:28 PM (38 days ago)
**Ensysce Biosciences, Inc. (ENSC) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** $1.32 million from federal grants, up from $0.31 million in Q1 2024. - **Operating Expenses:** $3.29 million, up from $2.15 million in Q1 2024, driven by increased research and development costs. - **Net Loss:** $1.95 million, improved from a net loss of $3.12 million in Q1 2024. - **Cash Flow:** Net cash used in operating activities was $1.71 million, down from $3.41 million in Q1 2024. Net cash provided by financing activities was $1.26 million, down from $5.69 million in Q1 2024. **Profit Margins:** - **Operating Margin:** -60% (improved from -173% in Q1 2024). - **Net Margin:** -147% (improved from -307% in Q1 2024). **Cash Flow:** - **Operating Cash Flow:** -$1.71 million (improved from -$3.41 million in Q1 2024). - **Financing Cash Flow:** $1.26 million (down from $5.69 million in Q1 2024). **Earnings Changes:** - **EPS:** -$1.39 (improved from -$8.21 in Q1 2024). **Quarterly Performance Discussion:** - Ensysce Biosciences, Inc. (ENSC) reported improved financial results for Q1 2025, with increased revenue from federal grants and reduced net loss compared to Q1 2024. - The company's operating expenses rose due to higher research and development costs, particularly for the PF614-MPAR program. - Ensysce's cash position improved, with $3.05 million in cash and cash equivalents as of March 31, 2025. - The company continues to face uncertainties regarding its ability to secure additional funding and achieve profitability. **Trends and Uncertainties:** - Ensysce is focused on advancing its lead product candidate, PF614, through Phase 3 clinical trials and developing its MPAR® technology. - The company's future operations and financial performance depend on its ability to secure additional funding, obtain regulatory approvals, and successfully commercialize its product candidates. - Ensysce faces risks related to clinical trial outcomes, regulatory approvals, competition, and intellectual property protection. **Future Operations Impact:** - Ensysce plans to continue investing in research and development, expand its intellectual property portfolio, and seek regulatory approvals for its product candidates. - The company may explore strategic transactions, such as collaborations or acquisitions, to support its growth and development efforts. - Ensysce's ability to execute its business strategy and achieve its goals depends on its ability to secure additional funding and manage its financial resources effectively.